Search results
Found 30016 matches for
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.
Norman Collisson Foundation Scholarship
Applications for this project are now closed.
Themes
OCTRU runs trials across multiple areas of medicine. Within OCTRU there are five core therapeutic areas of expertise, although trials are also undertaken outside of these areas and groups.
Meet Chris
-
Christopher Buckley
Kennedy Professor of Translational Rheumatology and Director of Clinical Research
